NTRA

Natera, Inc.
$272.96
+0.07 (+0.02%)
Mkt Cap 39.42B
Volume 457,933
52W Range 131.811-288.04
Sector Healthcare
Beta 1.50
EPS (TTM) -1.63
P/E Ratio -150.72
Revenue (TTM) 2.50B
Rev Growth (5Y) +42.6%
EPS Growth (5Y) N/A
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 2.31B 1.70B 1.08B 820.22M 625.49M 391.00M 302.33M 257.65M 210.94M 217.07M 190.35M 159.29M
Net Income (208.16M) (190.43M) (434.80M) (547.80M) (471.72M) (229.74M) (124.83M) (128.15M) (136.31M) (95.77M) (70.28M) (5.15M)
EPS -1.52 -1.53 -3.78 -5.57 -5.21 -2.84 -1.79 -2.22 -2.56 -1.86 -1.47 -0.14
Free Cash Flow 109.11M 69.24M (286.15M) (479.20M) (376.27M) (202.12M) (68.41M) (74.46M) (106.66M) (97.04M) (45.68M) 533,000
FCF / Share 0.80 0.56 -2.49 -4.87 -4.15 -2.49 -0.98 -1.29 -2.00 -1.89 -0.96 0.01
Operating CF 215.30M 135.66M (246.96M) (431.50M) (335.24M) (182.51M) (63.44M) (70.58M) (96.79M) (73.90M) (37.83M) 10.49M
Total Assets 2.51B 1.66B 1.44B 1.39B 1.24B 932.15M 582.66M 268.17M 214.61M 210.68M 265.24M 123.62M
Total Debt 214.38M 187.12M 441.99M 446.22M 397.23M 281.09M 155.81M 123.51M 123.18M 49.62M 42.09M 26.81M
Cash & Equiv 1.08B 945.59M 642.10M 466.09M 84.39M 48.67M 61.93M 46.41M 12.62M 15.26M 28.95M 87.18M
Book Value 1.71B 1.20B 765.33M 705.74M 653.30M 486.24M 278.71M 32.16M 25.42M 106.48M 184.76M (171.34M)
Return on Equity -0.12 -0.16 -0.57 -0.78 -0.72 -0.47 -0.45 -3.98 -5.36 -0.90 -0.38 N/A
NTRA News
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Jul 10, 2026 07:01 AM · zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Jul 09, 2026 05:56 AM · zacks.com
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
Jul 09, 2026 02:00 AM · businesswire.com
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Jul 06, 2026 02:00 AM · businesswire.com
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Jul 01, 2026 08:01 AM · zacks.com
Natera, Aveta partner on late-stage head and neck cancer trial
Jun 29, 2026 02:55 AM · reuters.com
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Jun 29, 2026 02:00 AM · businesswire.com
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
Jun 25, 2026 06:55 AM · zacks.com
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
Jun 25, 2026 05:06 AM · zacks.com
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Jun 25, 2026 03:00 AM · businesswire.com